Related Experiment Video
Updated: Oct 19, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
Pegvisomant in severe, treatment-resistant thyroid eye disease: a case report
Laura Köröskényi1, Noémi Szkibák1, Zita Steiber2
1Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Abstract:
Teprotumumab, a monoclonal antibody against the IGF1 receptor, has proven effective in the treatment of thyroid eye disease (TED). Pegvisomant reduces IGF1 levels through selective inhibition of growth hormone receptors. Here, we present a hypothesis-generating case of a 69-year-old patient with progressive TED. Pegvisomant 20 mg was administered daily for 90 days. IGF1 levels declined and remained low-normal during treatment. Clinical activity scores and VISA (vision, inflammation, strabismus and appearance) scores improved rapidly. MRI assessment showed that water content of both extraocular muscles and orbital connective tissue decreased after treatment. 99mTc-DTPA SPECT confirmed the decrease in disease activity. Further studies may confirm the efficacy of pegvisomant in TED.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Graves' Disease I: Introduction
Graves Disease II: Pathophysiology
Hyperthyroidism II: Pathophysiology
Hyperthyroidism I: Introduction